Four Trending Stocks Leading Biotech Sector on Heels of
Latest R&D and Innovative Drug Therapy
Advancements
Coral Springs, FL -- July 27, 2016 -- InvestorsHub
NewsWire -- With research and development being pivotal in the
advancing treatments for rare diseases and conditions, companies in
the biotech sector aim to remain competitive through continued
R&D activities, introduction of latest biomedical therapies and
mergers & acquisitions.
SeeThruEquity, the leading independent equity research firm
focused on smallcap and microcap public companies, today announced
it has initiated coverage on Q BioMed Inc. (OTCQB:
QBIO) with a price target of $3.85. The report is
available here: http://www.seethruequity.com/#!qbio/cxnb
QBIO is focused on identifying, acquiring and licensing
attractive biomedical assets from small private companies and
academia, which lack the resources and experience to bring their
programs to market on their own. QBIO believes it can add
considerable value to its investments by providing strategic
capital, industry resources and experience in order to accelerate
the development and commercialization of life science assets.
QBIOs initial program is MAN-01, a small molecule designed to treat
glaucoma, an eye disease which affects 60mn people globally, and is
expected to affect over 100mn people by 2020E. The glaucoma
market is a $5 billion annual market opportunity, for which no new
drugs have been approved in approximately 20 years. The
company acquired an exclusive license to MAN-01 from Mannin
Research, Inc. The technology platform is based on the research of
Dr. Susan Quaggin, Chief Scientific Officer of Mannin Research.
Broadly, Dr. Quaggin's research demonstrates a unique approach to
treating a host of vascular diseases including glaucoma, cystic
kidney disease, influenza, ebola, and others. These
additional indications are part of the exclusive license agreement
with Mannin. In addition to the Mannin Research platform
technology, QBIO has announced its intention to acquire 2-3
additional programs over the next twelve months.
Read the full Q BioMed (OTC:
QBIO) release at: http://financialnewsmedia.com/profiles/qbio.html
In our view the experience and quality of management should a
crucial role in the successful execution of the biomedical
accelerator model. Indeed, the core value promised by QBIO is
that it will be able to identify, develop, and support
value-creating programs harvested from small private biomedical
companies and academia, providing a conduit which would otherwise
be difficult to access or unavailable to pubic company investors
and then provide strategic capital and other valuable resources to
these companies to help them reach commercialization and/or a
value-creating event. QBIO is led by CEO Denis Corin, who
brings a wealth of experience in the biomedical field at both large
pharmaceutical firms and small innovative firms in the biotech
space, stated Ajay Tandon, CEO of SeeThruEquity. We see serval
potential catalysts for the company in coming months, including the
pending acquisition of a new cancer palliation drug. We are
initiating coverage with a price target of $3.85.
Q BioMed Inc. is to be featured on CEO Clips on The Documentary
Channel as well as Thomson Reuters Insider Network at http://reut.rs/29TZ6Th. CEO Clips, a series
which profiles the most innovative publicly traded companies in
North America, will feature QBIO on The Documentary Channel in
August, Monday through Friday, throughout the day
and evenings.
In other Biotech advancing leaders in the markets this
week: Elite Pharmaceuticals, Inc. (OTCQB:
ELTP) recently announced that the U.S. Food and Drug
Administration (the FDA) has issued a Complete Response Letter (the
CRL) regarding the New Drug Application (the NDA) for SequestOx
(oxycodone hydrochloride and naltrexone hydrochloride), Elites
investigational abuse-deterrent opioid candidate for the management
of moderate to severe acute pain where the use of an opioid
analgesic is appropriate.
MEDIFIRST SOLUTIONS, INC. (OTC:
MFST) recently updated shareholders regarding its flagship
product, the infrared Time Machine TTML-8102000 Laser Thermal
Therapeutic Device. As recently announced, the Company, in response
to its Premarket Notification 510(k) submission for "The Time
Machine" Series Laser, received clearance from the U.S. Food and
Drug Administration ("FDA") to market its infrared Time Machine
TTML-8102000 Laser Thermal Therapeutic Device.
Anavex Life Sciences Corp. (NASDAQ:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental diseases including Alzheimers disease, other
central nervous system (CNS) diseases, pain and various types of
cancer, recently announced data from the first of two posters at
the Alzheimers Association International Conference (AAIC)
2016.
FinancialNewsMedia.com is leading provider of third party
publishing & news dissemination services. If you would
like more information regarding our news coverage solutions, please
visit financialnewsmedia.com for more details. Get
an edge on the market with our Premium News Alerts that are FREE
for a limited time at financialnewsmedia.com. Follow us
on Facebook: facebook.com/financialnewsmedia and
Twitter: twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party
publisher and news dissemination service provider, which
disseminates electronic information through multiple online media
channels. FNMG is NOT affiliated in any manner with any
company mentioned herein. FNMG and its affiliated companies
are a news dissemination solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment
licenses and may NOT sell, offer to sell or offer to buy any
security. FNMG's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to
be strictly informational and is NEVER to be construed or
interpreted as research material. All readers are strongly
urged to perform research and due diligence on their own and
consult a licensed financial professional before considering any
level of investing in stocks. All material included herein is
republished content and details which were previously disseminated
by the companies mentioned in this release. FNMG is not
liable for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all
or a portion of their investment when investing in stocks.
For current services performed FNMG has been compensated three
thousand seven hundred dollars for news coverage of the current
press release issued by Q BioMed Inc. by the company. FNMG
HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and FNMG undertakes no
obligation to update such statements.
Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
SOURCE: FN Media Group, LLC.
